Pharma Aids Limited announcements
270 Dhaka Stock Exchange announcements for Pharma Aids Limited (PHARMAID) since 2007: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2024 (24).
- Resumption after Record Date
Trading of the shares of the company will resume on 08.12.2024.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 05.12.2024.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 03.12.2024 to 04.12.2024 and trading of the shares will remain suspended on record date i.e., 05.12.2024.
- Qualified Opinion
The auditor of the company has given the "Qualified Opinion" paragraph in the audited financial statement of the company for the year ended June 30, 2024. To view the details please visit: https://www.dsebd.org/Auditors_opinion/2024/November/PHARMAID_2024.pdf
- Regarding New Machinery Investment & Land Revaluation for Q2 Accounts
The company has informed that the Board, in order to meet the rising market demand, has decided to invest Company's own fund to import 01(one) complete line of brand new machine within June 2025 for manufacturing ampoules and expanding production. The Board has also approved the revaluation amount of the Company's existing factory land as per the land valuation report. dated 26-10-2024. by Fames & R Chartered Accountants. (cont.) (cont. news of PHARMAID): to be reflected in the accounts of second quarter as below: Land Amount: 36.00 decimal, Location: Chandra, Kaliakoir, Gazipur, Book Value (Tk.) as on 30-09-2024: 80,811.00, Revaluation Amount (Tk.) as on 26-10-2024: 3,60,00,000.00, Adjustment in Value (Tk.): 3,59,19,189.00. (end)
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 5.66 for July-September 2024 as against Tk. 3.68 for July-September 2023; NOCFPS was Tk. 0.43 for July-September 2024 as against Tk. 3.29 for July-September 2023. NAV per share was Tk. 115.52 as on September 30, 2024 and Tk. 109.89 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
- Dividend Declaration
The Board of Directors has recommended 25% cash dividend for the year ended June 30, 2024. Date of AGM: 24.12.2024, Time: 11:30 AM, Venue: Digital Platform. Record date: 05.12.2024. The Company has reported EPS of Tk. 19.61, NAV per share of Tk. 109.89 and NOCFPS of Tk. 7.30 for the year ended June 30, 2024 as against Tk. (2.05), Tk. 91.28 and Tk. 2.33 respectively for the year ended June 30, 2023. (cont.) (Continuation news of PHARMAID): Reasons for significant deviation in EPS: The increase in selling price, the toll production, coupled with raw material cost minimization efforts, greatly reduced overhead costs per unit and contributed significantly to sales and profit which resulted in significant deviation in EPS compared to last year. Whereas, 25% Cash Dividend is recommended keeping in mind the necessity of funds for land acquisition and upcoming BMRE project. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (07.11.2024) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 06, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
- Resumption after Record date
Trading of the shares of the company will resume on 19.06.2024.
- Suspension for Record date
Trading of the shares of the company will remain suspended on record date i.e., 13.06.2024 for EGM.
- Spot for EGM
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle from 11.06.2024 to 12.06.2024 and trading of the shares will remain suspended on record date i.e., 13.06.2024 for EGM.
- Regarding EGM platform
Refer to their earlier news disseminated by DSE on 26.05.2024 regarding decision to hold EGM for purchase of land, the company has further informed that the 1st EGM of the company will be held on June 24, 2024 at 11:30 AM using Digital Platform at the link-https://bit.ly/palegm to approve the purchase of total 103.00 decimal lands.
- The Company has informed that the Board of Directors has decided to purchase 103.00 decimal land adjacent to Nabinagar-C
The Company has informed that the Board of Directors has decided to purchase 103.00 decimal land adjacent to Nabinagar-Chandra highway at Mouza: Chandora, PS & SRO: Kaliakoir, District: Gazipur, for a total investment up to Tk. 11,38,00,000.00 (Eleven Crore Thirty-Eight Lac) only, excluding the cost for registration and other related expenses, and depending on the availability of necessary funds (cont.)
- Decision to hold EGM for purchase of land
(Cont. news of PHARMAID): for construction of the state-of-the-art manufacturing plant and expansion of production capacity of glass ampoules with a scope for product diversification in future, subject to the approval by the shareholders at the Extraordinary General Meeting (EGM) to be held on June 24, 2024. Time of the EGM: 11:30 AM, Digital platform link: To be notified in due time. Record Date for EGM: June 13, 2024. (end)
The first part of this announcement is missing from the archive. - (Q3 Un-audited): EPS was Tk. 7.46 for January-March 2024 as against Tk. (1.21) for January-March 2023; EPS was Tk. 18.37
(Q3 Un-audited): EPS was Tk. 7.46 for January-March 2024 as against Tk. (1.21) for January-March 2023; EPS was Tk. 18.37 for July 2023-March 2024 as against Tk. 0.05 for July 2022-March 2023. NOCFPS was Tk. 12.81 for July 2023-March 2024 as against Tk. 5.52 for July 2022-March 2023. NAV per share was Tk. 108.64 as on March 31, 2024 and Tk. 91.28 as on June 30, 2023. (cont.)
- Q3 Financials
(Cont. news of PHARMAID): Reasons for deviation in EPS, NOCFPS and NAVPS: EPS has been increased due to increase in selling price and volume of glass ampoules sold. Apart from that toll production contributed to significant increase in sales. NOCFPS has been increased due to increase in collection from revenue and others. NAVPS has been increased due to increase in sales revenue and retained earnings. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 24, 2024 at 03:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2023 to the respective shareholders.
- (Q2 Un-audited): EPS was Tk. 7.21 for October-December 2023 as against Tk. (0.76) for October-December 2022; EPS was Tk.
(Q2 Un-audited): EPS was Tk. 7.21 for October-December 2023 as against Tk. (0.76) for October-December 2022; EPS was Tk. 10.90 for July-December 2023 as against Tk. 1.23 for July-December 2022. NOCFPS was Tk. 10.30 for July-December 2023 as against Tk. 2.92 for July-December 2022. NAV per share was Tk. 101.18 as on December 31, 2023 and Tk. 91.28 as on June 30, 2023. Reasons for deviation in EPS, NOCFPS and NAV: (cont.)
- Q2 Financials
(Cont. news of PHARMAID): EPS significantly increased compared to previous year's 2nd quarter because of increase in selling price and volume of glass ampoules. However, this increasing trend may be adversely affected in the following quarters due to extreme volatility of the US Dollar exchange rate which is only rising day by day. Increase in NOCFPS arise due to increase in collection from revenue and others. NAV has increased due to increase in sales revenue and increase in retained earnings. (end)
The first part of this announcement is missing from the archive. - Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
- National Credit Ratings Limited (NCR) has announced the surveillance entity rating of the Company as \"A-\" in the long
National Credit Ratings Limited (NCR) has announced the surveillance entity rating of the Company as \"A-\" in the long term and \"ST-3\" in the short term along with developing outlook based on audited financial statements as on June 30, 2023.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.